The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 27, 2010
Filed:
Feb. 14, 2006
Jay K. Kolls, Sewickley, PA (US);
Florencia Marine Mcallister, Pittsburgh, PA (US);
Beatriz M. Carreno, Clayton, MO (US);
Samuel J. Goldman, Acton, MA (US);
Jay K. Kolls, Sewickley, PA (US);
Florencia Marine McAllister, Pittsburgh, PA (US);
Beatriz M. Carreno, Clayton, MO (US);
Samuel J. Goldman, Acton, MA (US);
Wyeth LLC, Madison, NJ (US);
University of Pittsburgh of the Commonwealth System of Higher Education, Pittsburgh, PA (US);
Abstract
The invention is related to findings that IL-17F-mediated inflammation of airway passages may be mediated via signaling through IL-17R on the basolateral surface of human respiratory epithelial cells. Thus, the present invention provides isolated and purified IL-17F or IL-17R polynucleotides and polypeptides. The present invention also is directed to novel methods for screening test compounds capable of inhibiting, i.e., decreasing, limiting, blocking, or otherwise reducing, IL-17F bioactivity, and methods for diagnosing, prognosing, and monitoring the progress of, disorders related to IL-17F bioactivity, e.g., disorders related to the effects of IL-17F binding to IL-17R on airway inflammation, e.g., in patients with cystic fibrosis, including pulmonary exacerbations due to bacterial infections in same. The present invention is further directed to novel therapeutics and therapeutic targets and to methods for the intervention (treatment) and prevention of said disorders related to IL-17F bioactivity.